Financière de Tubize S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TUB.BR research report →
About the company
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
- CEO
- Eric Nys
- IPO
- 2000
- Employees
- 3
- HQ
- Brussels, BE
Price Chart
- Market Cap
- $9.69B
- P/E
- 103.75
- P/S
- 0.00
- P/B
- 5.14
- EV/EBITDA
- -3269.63
- Div Yield
- 0.51%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 4.88%
- ROIC
- -0.16%
- Revenue
- $0 · -100.00%
- Net Income
- $93.23M · 3.47%
- EPS
- $2.09 · 3.47%
- Op Income
- $-2,968,579
- FCF YoY
- 4539.00%
- 52W High
- $250.50
- 52W Low
- $128.80
- 50D MA
- $213.37
- 200D MA
- $214.72
- Beta
- 0.40
- Avg Volume
- 31.59K
Get TickerSpark's AI analysis on TUB.BR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TUB.BR coverage
Recent articles, reports, and earnings notes.
No research on TUB.BR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TUB.BR report →Similar companies
Peers in the same neighborhood.